Novo is suing Hims & Hers to halt obesity drug copycats [Los Angeles Times (CA)]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Los Angeles Times
Hims is breaching the US patent on semaglutide, the active ingredient in Novo's blockbuster obesity treatments, Novo argued Monday. The US lawsuit attacks not only Hims's new strategy to launch a copycat pill but also goes after shots that mimic Wegovy and its sister drug Ozempic. The move marks a more aggressive approach for Novo under Chief Executive Officer Mike Doustdar. Until now, the drugmaker's legal strategy focused on the way that companies like Hims market their products. Novo said it's the first time it has sued over patent infringement for compounded semaglutide. The decision escalates Novo's spat with Hims despite the US platform's retreat on Saturday, when it said it would stop offering cheaper versions of the new Wegovy pill meant to fuel the Danish drugmaker's comeback. The Hims decision to launch a knock-off Wegovy pill was “a step too far,” John Kuckelman, general counsel at Novo, said in an interview. “Last week's announcement was egregious and it was definit
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $1,200.00 to $1,285.00. They now have a "buy" rating on the stock.MarketBeat
- Lilly to acquire Orna Therapeutics to advance cell therapiesPR Newswire
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Leerink Partners from $1,234.00 to $1,296.00. They now have an "outperform" rating on the stock.MarketBeat
- Goldman Sachs Reaffirms Buy on Eli Lilly and Company (LLY), Citing 25% Growth Outlook [Yahoo! Finance]Yahoo! Finance
- Weight-loss drugs to compete on biggest stage with Super Bowl ads [Yahoo! Finance Canada]Yahoo! Finance Canada
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 2/4/26 - Form 8-K
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- LLY's page on the SEC website